| Literature DB >> 28703780 |
Hany M Yehia1,2, Ebtesam M Al-Olayan3,4, Manal F El-Khadragy5,6,7, Dina M Metwally8,9,10.
Abstract
Bacterial infections of cutaneous leishmaniasis cause skin ulcers on mice, resulting in increased tissue deterioration, and these infections can be controlled with liquid allicin. To isolate and identify the incidences of real secondary bacterial infections in mice, we performed the current study by injecting mice (n = 50) with Leishmania major. L. major infections were initiated by an intramuscular injection of 0.1 mL Roswell Park Memorial Institute (RPMI 1640 media/mouse (107 promastigote/mL)). Scarring appeared 2-6 weeks after injection, and the bacteria were isolated from the skin ulcer tissues. Allicin (50 µL/mL) and ciprofloxacin (5 μg; Cip 5) were used for controlling L. major and bacteria. One hundred samples from skin ulcers of mice were examined, and 200 bacterial colonies were isolated. Forty-eight different genera and species were obtained and identified by Gram staining and physiological and biochemical characterization using identification kits. All samples were positive for secondary bacterial infections. Of the isolates, 79.16% were identified as Gram-negative bacteria, and 28.84% were identified as Gram-positive bacteria; only one yeast species was found. Interestingly, pure allicin liquid at a concentration 50 µL/mL exhibited antibacterial activity against a wide range of Gram-negative and some Gram-positive bacteria, in addition to yeast, and was 71.43% effective. Antimicrobial resistance patterns of all genera and species were determined using 15 different antibiotics. Allicin (50 µL/mL) and Cip 5 were the most effective against L. major and 92.30% of isolated bacteria. Stenotrophomonas maltophilia was the most resistant bacterium to the tested antibiotics with a survival rate of 73.33%, and it exhibited resistance to allicin.Entities:
Keywords: Leishmania major; bacteria; ciprofloxacin; cutaneous leishmaniasis; histopathological analysis
Mesh:
Substances:
Year: 2017 PMID: 28703780 PMCID: PMC5551215 DOI: 10.3390/ijerph14070777
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Lesion caused by Leishmania major infection in a female hamster right foot pad.
Figure 2(A,B) Cutaneous leishmaniasis scars of Bagg Albino genotype c (BALB/c) mice appeared on the skin of mice four weeks after injection.
Figure 3(A,B) Light micrograph (LM) of skin-infected mice at four weeks post-infection with 0.1 mL of 107/mL promastigotes of Leishmania major, d: showing the intact histological structure of the epidermis and dermis, and a very large amount of inflammatory cell infiltration and fibroblastic proliferation in the subcutaneous layer (m).
Lesion size (mm) in mouse skin one and four weeks after infection and treatment.
| Doses | First Week | Four Weeks | |
|---|---|---|---|
| Mean ± SD | Mean ± SD | ||
| Control (Infected, non-treated) | 8.22 ± 0.88 | 10.8 ± 1.89 | <0.0001 |
| Liquid allicin (0.30 μM/mouse) | 7.88 ± 1.67 | 5.65 ± 1.01 | 0.107 |
| Ciprofloxacin (10 mg/mL) | 7.43 ± 1.99 | 6.79 ± 1.16 | 0.775 |
| Allicin (0.30 μM + Ciprofloxacin (10 mg/mL)) | 7.66 ± 1.97 | 3.17 ± 1.12 | 0.058 * |
SD: Standard Deviation * Significant at p < 0.05.
Percentages of Gram-positive and -negative microorganisms isolated from cutaneous leishmaniasis in skin ulcers of mice.
| Microorganism | Gram Stain | Total Isolates ( | % |
|---|---|---|---|
| − | 2 | 4.16 | |
| − | 2 | 4.16 | |
| − | 4 | 8.33 | |
| − | 2 | 4.16 | |
| − | 2 | 4.16 | |
| − | 4 | 8.33 | |
| − | 4 | 8.33 | |
| − | 2 | 4.16 | |
| − | 2 | 4.16 | |
| − | 4 | 8.33 | |
| + | 2 | 4.16 | |
| + | 4 | 8.33 | |
| + | 2 | 4.16 | |
| − | 2 | 4.16 | |
| − | 6 | 12.5 | |
| − | 2 | 4.16 | |
| + | 2 | 4.16 | |
| Gram-positive | + | 10 | 20.84 |
| Gram-negative | − | 38 | 79.16 |
The effect of liquid allicin at 50 µL (disc diffusion) on bacterial isolates as a zone of inhibition (mm).
| Bacterial Isolates | Allicin Zone of Inhibition (mm) |
|---|---|
| 15 | |
| 15 | |
| − | |
| − | |
| 10 | |
| 12 | |
| − | |
| 10 | |
| 10 | |
| 10 | |
| 15 | |
| 10 | |
| 15 | |
| − | |
| Efficiency rate (%) | 71.43 |
Antimicrobial resistance of 24 h cultured bacterial isolates based on the development of inhibitory zone diameters after application of discs containing specific antimicrobial agents.
| % | E | CFR | TE | C | K | CIP | CT | SXT | LZD | F | VA | TIC | N | AMP | AML | Antibiotic | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Resistance | 15 | 30 | 30 | 30 | 30 | 5 | 25 | 25 | 30 | 300 | 30 | 75 | 30 | 25 | 25 | ||
| ≤13 | ND | ≤11 | ≤12 | ≤13 | ≤15 | ND | ≤10 | ≤20 | ≤14 | ≤13 | ≤11 | ≤13 | ≤13 | ≤13 | R | Microorganism | |
| 14–22 | 12–14 | 13–17 | 14–17 | 16–20 | 11–15 | 21–22 | 15–16 | 14–18 | 12–14 | 14–15 | 14–16 | 14–17 | I | ||||
| ≥23 | ≥15 | ≥18 | ≥18 | ≥21 | ≥16 | ≥23 | ≥17 | ≥19 | ≥15 | ≥16 | ≥17 | ≥18 | S | ||||
| 60 | R | R | 15 | 15 | 15 | 30 | 15 | 25 | R | R | R | R | R | R | R | ||
| 0 | 17 | 30 | 15 | 15 | 30 | 30 | 16 | 30 | 30 | 24 | 30 | 30 | 15 | 30 | 30 | ||
| 0 | 25 | 30 | 20 | 18 | 30 | 30 | 10 | 25 | 24 | 20 | 20 | 30 | 20 | 30 | 20 | ||
| 60 | R | R | 13 | R | 20 | 30 | 13 | R | R | R | R | 12 | 15 | R | R | ||
| 26.67 | 16 | ND | 25 | 15 | 25 | 25 | 10 | R | R | R | R | 30 | 20 | 20 | 20 | ||
| 26.67 | 15 | 20 | 24 | 18 | 20 | 30 | 20 | 30 | R | 26 | R | 12 | 16 | R | R | ||
| 20 | 14 | R | 20 | R | R | 20 | 10 | 30 | 30 | 18 | 20 | 25 | 16 | 26 | 25 | ||
| 60 | 16 | R | 14 | 30 | R | 30 | R | 30 | R | R | 15 | R | R | R | R | ||
| 46.67 | 14 | R | 20 | 20 | R | R | R | 15 | R | R | 14 | 12 | R | 14 | 18 | ||
| 66.67 | R | R | R | 15 | 20 | 30 | 12 | 20 | R | R | R | R | R | R | R | ||
| 66.67 | R | R | 12 | 14 | R | 30 | 15 | 25 | R | R | R | R | R | R | R | ||
| 33.33 | R | 12 | 12 | 15 | 20 | 20 | 14 | 20 | R | 15 | R | 13 | 20 | R | R | ||
| 73.33 | R | R | R | 20 | R | 25 | 14 | R | R | R | R | R | R | R | R | ||
| 6 | 7 | 2 | 2 | 5 | 1 | 2 | 3 | 10 | 8 | 8 | 5 | 6 | 8 | 8 | Resistance number for each antibiotic | ||
| 46.15 | 53.8 | 15.39 | 15.39 | 38.46 | 7.70 | 15.38 | 23.08 | 76.92 | 61.54 | 61.54 | 38.46 | 46.15 | 61.54 | 61.5 | Resistance rate (%) | ||
| 83.85 | 30.7 | 84.61 | 84.61 | 61.54 | 92.30 | 84.61 | 76.92 | 23.08 | 38.46 | 38.46 | 61.54 | 83.85 | 38.46 | 38.4 | Sensitivity rate (%) | ||
Mean zones of inhibition for common antibiotics tested: ≥18 mm (S = sensitive), 13–17 mm (I = intermediate), <13 mm (R = resistant), except noted above and ND = not detected: treated as a common antibiotics inhibition zone. AMP 25 = ampicillin (25 μg), AML 25 = amoxicillin (25 μg), N 30 = neomycin (30 μg), TIC 75 = ticarcillin (75 μg), VA 30 = vancomycin (30 μg), F 300 = nitrofurantoin (300 μg), LZD 30 = linezolid (30 μg), SXT 25 = sulfamethoxazole trimethoprim (25 μg), CT 25 = colistin sulfate (25 μg), Cip 5 = ciprofloxacin (5 μg), K 30 = kanamycin (30 μg), C 30 = chloramphenicol (30 μg), TE 30 = tetracycline (30 μg), CFR 30 = cefadroxil (30 μg), and E 15 = erythromycin (15 μg).
Figure 4(A,B) Cutaneous leishmaniasis scars of BALB/c mice disappeared after treatments (four weeks post infection), with allicin and Cip.
Figure 5(A,B) LM of skin infected treated mouse at four weeks post-infection with 0.1 mL of 107/mL promastigotes of Leishmania major, showing normal histological structure of epidermis and dermis. Arrows point to inflammatory cell infiltration in dermal and subcutaneous tissue (m) H-EX40.